keyword
MENU ▼
Read by QxMD icon Read
search

treatment hemoglobin prostate cancer

keyword
https://www.readbyqxmd.com/read/28545997/factors-associated-with-survival-following-radium-223-treatment-for-metastatic-castration-resistant-prostate-cancer
#1
William W Wong, Eric M Anderson, Homan Mohammadi, Thomas B Daniels, Steve E Schild, Sameer R Keole, C Richard Choo, Katherine S Tzou, Alan H Bryce, Thai H Ho, Fernando J Quevedo, Sujay A Vora
BACKGROUND: Radium-223 ((223)Ra) improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This retrospective analysis was performed to better understand its efficacy in routine clinical practice and identify factors associated with survival. MATERIALS AND METHODS: Sixty-four patients with mCRPC who received (223)Ra between 2013 and 2015 were the basis of this retrospective study. Clinical outcomes and patient characteristics were obtained...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28537928/differences-in-risk-factors-of-malignancy-between-men-and-women-with-type-2-diabetes-a-retrospective-case-control-study
#2
Mariusz Dąbrowski, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński, Leszek Czupryniak
BACKGROUND: The aim of this multicenter, retrospective, case-control study was to identify differences in risk factors of malignancy between men and women with type 2 diabetes. RESULTS: Among women the most prevalent malignancies were: breast and uterine cancers (35.6% and 14.4% respectively), while among men there were: colorectal and prostate cancers (24.5% and 13.3% respectively). In both gender metformin use was associated with lower cancer risk. Obesity and insulin treatment in dose-dependent and time-varying manner were associated with significantly increased risk of malignancy in females...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28534688/coexisting-prostate-cancer-and-diabetes-mellitus-implications-for-patient-outcomes-and-care
#3
Nina J Karlin, Shailja B Amin, Patricia M Verona, Heidi E Kosiorek, Curtiss B Cook
OBJECTIVE: To investigate how diabetes mellitus (DM) impacts short-term overall survival for patients with prostate cancer and to examine how prostate cancer impacts glycemic control in DM. METHODS: Patients with DM and prostate cancer newly diagnosed from 2007-2014 were identified from the institutional cancer registry and matched to patients with prostate cancer but no DM according to age and year of prostate cancer diagnosis. RESULTS: The study included 276 cases and 276 controls; the mean age was 72 years, most (93%) were white, the most common Gleason score (52%) was 7, and the majority (56%) were tumor stage II...
May 23, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28126272/prostate-specific-antigen-response-in-black-and-white-patients-treated-with-abiraterone-acetate-for-metastatic-castrate-resistant-prostate-cancer
#4
Sundhar Ramalingam, Michael S Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R Harrison, Andrew J Armstrong, Daniel J George, Tian Zhang
PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. METHODS: We performed a retrospective case-control study of B vs...
June 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28068151/prognostic-impact-of-pretreatment-neutrophil-to-lymphocyte-ratio-in-castration-resistant-prostate-cancer-patients-treated-with-first-line-docetaxel
#5
Consuelo Buttigliero, Chiara Pisano, Marcello Tucci, Francesca Vignani, Valentina Bertaglia, Davide Iaconis, Pamela Guglielmini, Gianmauro Numico, Giorgio V Scagliotti, Massimo Di Maio
BACKGROUND: The neutrophil-to-lymphocyte ratio (NLR), a measure of systemic inflammatory response, has been associated with poor outcome in several solid tumors, including prostate cancer. We retrospectively investigated the prognostic role of pretreatment NLR in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel. METHODS: All CRPC patients treated with first-line docetaxel at two Italian institutions, with available data about baseline neutrophil and lymphocyte values, were included in this retrospective analysis...
April 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28003740/dose-dependent-effects-of-cisplatin-on-the-severity-of-testicular-injury-in-sprague-dawley-rats-reactive-oxygen-species-and-endoplasmic-reticulum-stress
#6
Kiran Kumar Soni, Hye Kyung Kim, Bo Ram Choi, Keshab Kumar Karna, Jae Hyung You, Jai Seong Cha, Yu Seob Shin, Sung Won Lee, Chul Young Kim, Jong Kwan Park
Cisplatin (CIS) is used in the treatment of cancer, but its nonspecific systemic actions lead to toxic effects on other parts of the body. This study investigated the severity of CIS toxicity by increasing its dose over a constant time period. Sprague Dawley rats were divided into five treatment groups and control group with CIS (2, 4, 6, 8, and 10 mg/kg) administered intraperitoneally for 5 days. The body and organs were weighed, epididymal sperm was counted, and sperm motility and sperm apoptosis were evaluated...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27651103/radium-223-use-in-clinical-practice-and-variables-associated-with-completion-of-therapy
#7
Rana R McKay, Susanna Jacobus, Matthew Fiorillo, Elisa M Ledet, Patrick M Cotogna, Allie E Steinberger, Heather A Jacene, Oliver Sartor, Mary-Ellen Taplin
BACKGROUND: Radium-223 has shown clinical efficacy in metastatic castration-resistant prostate cancer. Despite improvement in quality of life and survival, practice patterns and utility of this agent outside the context of clinical trials have not been fully characterized. The primary objective in this study was to evaluate variables associated with completion of 5 to 6 radium-223 doses. PATIENTS AND METHODS: We conducted retrospective analyses of patients who received radium-223 (n = 135)...
August 20, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27613490/hematologic-safety-of-radium-223-dichloride-baseline-prognostic-factors-associated-with-myelosuppression-in-the-alsympca-trial
#8
Nicholas J Vogelzang, Robert E Coleman, Jeff M Michalski, Sten Nilsson, Joe M O'Sullivan, Christopher Parker, Anders Widmark, Marcus Thuresson, Lei Xu, Joseph Germino, Oliver Sartor
BACKGROUND: Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk factors will improve clinical decision making. We describe hematologic safety of radium-223 in ALSYMPCA and post hoc analyses identifying patients at increased risk for hematologic toxicity. PATIENTS AND METHODS: Hematologic parameters and adverse events were analyzed...
August 8, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27586506/a-comparative-study-on-the-efficacies-of-gonadotropin-releasing-hormone-gnrh-agonist-and-gnrh-antagonist-in-neoadjuvant-androgen-deprivation-therapy-combined-with-transperineal-prostate-brachytherapy-for-localized-prostate-cancer
#9
Kenta Miki, Hiroshi Sasaki, Masahito Kido, Hiroyuki Takahashi, Manabu Aoki, Shin Egawa
BACKGROUND: Neoadjuvant androgen deprivation therapy (ADT) has been suggested to confer several clinical benefits in patients with prostate cancer (PCa) undergoing transperineal prostate brachytherapy (TPPB). Unlike gonadotropin-releasing hormone (GnRH) receptor agonists, a GnRH antagonist such as degarelix can achieve castrate levels of testosterone without testosterone flare. However, normalization of serum testosterone levels following completion of neoadjuvant ADT in either form of treatment has never been compared in clinical trials...
September 1, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27551494/functional-characterization-of-the-ectopically-expressed-olfactory-receptor-2at4-in-human-myelogenous-leukemia
#10
S Manteniotis, S Wojcik, P Brauhoff, M Möllmann, L Petersen, J R Göthert, W Schmiegel, U Dührsen, G Gisselmann, H Hatt
The olfactory receptor (OR) family was found to be expressed mainly in the nasal epithelium. In the last two decades members of the OR family were detected to be functional expressed in different parts of the human body such as in liver, prostate or intestine cancer cells. Here, we detected the expression of several ORs in the human chronic myelogenous leukemia (CML) cell line K562 and in white blood cells of clinically diagnosed acute myeloid leukemia (AML) patients by RT-PCR and next-generation sequencing...
2016: Cell Death Discovery
https://www.readbyqxmd.com/read/27515296/uncontrolled-diabetes-predicts-poor-response-to-novel-antiandrogens
#11
Theodoros Karantanos, Styliani Karanika, Gretchen Gignac
Metabolic abnormalities including hyperglycemia and hyperlipidemia have been associated with worse prognosis of prostate cancer (PCa), but there are limited data regarding their impact on the prognosis of castrate-resistant prostate cancer (CRPC) and the response of novel antiandrogens, namely abiraterone acetate (AA) and enzalutamide. Retrospective analysis of 61 patients with CRPC on AA or enzalutamide, treated at the Boston Medical Center, was performed. We evaluated hemoglobin A1c (HbA1c), HDL, LDL, Triglycerides and BMI within 2months before the initiation of treatment with AA or enzalutamide and progression-free survival (PFS) under this treatment...
September 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27506431/-177-lu-dkfz-psma-617-therapy-in-metastatic-castration-resistant-prostate-cancer-safety-efficacy-and-quality-of-life-assessment
#12
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, (177)Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC). METHODS: Thirty-one mCRPC patients with progressive disease despite second-line hormonal therapy and/or docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic(68)Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Included patients then underwent quarterly (177)Lu-DKFZ-PSMA-617 therapy...
January 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27436076/effects-of-8-year-treatment-of-long-acting-testosterone-undecanoate-on-metabolic-parameters-urinary-symptoms-bone-mineral-density-and-sexual-function-in-men-with-late-onset-hypogonadism
#13
Sompol Permpongkosol, Kalayanee Khupulsup, Supatra Leelaphiwat, Sarawan Pavavattananusorn, Supranee Thongpradit, Thanom Petchthong
INTRODUCTION: The long-term effects of long-acting testosterone undecanoate (TU) and androgen receptor CAG repeat lengths in Thai men with late-onset hypogonadism (LOH) have not been reported. AIM: To analyze the 8-year follow-up effects of intramuscular TU therapy on metabolic parameters, urinary symptoms, bone mineral density, and sexual function and investigate CAG repeat lengths in men with LOH. METHODS: We reviewed the medical records of 428 men with LOH who had been treated with TU and 5 patients were diagnosed with prostate cancer during TU therapy...
August 2016: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/27401636/survival-outcomes-of-concurrent-treatment-with-docetaxel-and-androgen-deprivation-therapy-in-metastatic-castration-resistant-prostate-cancer
#14
Ho Seong Jang, Kyo Chul Koo, Kang Su Cho, Byung Ha Chung
PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we aimed to assess the impact of the combined use of androgen deprivation therapy (ADT) with DTX for mCRPC. MATERIALS AND METHODS: We performed a single-institutional retrospective analysis of patients with mCRPC who received either DTX alone (DTX group, n=21) or concurrent DTX and ADT (DTX+ADT group, n=26) between August 2006 and February 2014...
September 2016: Yonsei Medical Journal
https://www.readbyqxmd.com/read/27246360/castration-resistant-prostate-cancer-tissue-acquisition-from-bone-metastases-for-molecular-analyses
#15
David Lorente, Aurelius Omlin, Zafeiris Zafeiriou, Daniel Nava-Rodrigues, Raquel Pérez-López, Carmel Pezaro, Niven Mehra, Elizabeth Sheridan, Ines Figueiredo, Ruth Riisnaes, Susana Miranda, Mateus Crespo, Penny Flohr, Joaquín Mateo, Amelia Altavilla, Roberta Ferraldeschi, Diletta Bianchini, Gerhardt Attard, Nina Tunariu, Johann de Bono
BACKGROUND: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB. MATERIALS AND METHODS: A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set...
December 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27131465/testosterone-therapy-in-patients-with-treated-and-untreated-prostate-cancer-impact-on-oncologic-outcomes
#16
Jesse Ory, Ryan Flannigan, Colin Lundeen, James G Huang, Peter Pommerville, S Larry Goldenberg
PURPOSE: Testosterone deficiency and prostate cancer have an increasing prevalence with age. However, because of the relationship between prostate cancer and androgen receptor activation, testosterone therapy among patients with known prostate cancer has been approached with caution. MATERIALS AND METHODS: We identified a cohort of 82 hypogonadal men with prostate cancer who were treated with testosterone therapy. They included 50 men treated with radiation therapy, 22 treated with radical prostatectomy, 8 on active surveillance, 1 treated with cryotherapy and 1 who underwent high intensity focused ultrasound...
October 2016: Journal of Urology
https://www.readbyqxmd.com/read/27103427/lhrh-analog-therapy-is-associated-with-worse-metabolic-side-effects-than-bilateral-orchiectomy-in-prostate-cancer
#17
Andreza Vargas, Roberto Dias Machado, Daniel Ianni Filho, Carlos Eduardo Paiva, Rodolfo Borges Dos Reis, Marcos Tobias-Machado, Eliney Ferreira Faria
PURPOSE: The morbidity associated with metabolic syndrome induced by androgen deprivation therapy (ADT) in prostate cancer (PCa) has not been widely studied. There are no studies comparing surgical and pharmacological castration with regards to their metabolic side effects. The aim of this study was to compare both modalities. METHODS: A prospective observational study was conducted in men with PCa and with indications of any ADT. The participants were divided into two groups: (1) bilateral orchiectomy and (2) LHRH analogs...
December 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27102406/predictors-of-chemotherapy-induced-toxicity-and-treatment-outcomes-in-elderly-versus-younger-patients-with-metastatic-castration-resistant-prostate-cancer
#18
Per Kongsted, Inge Marie Svane, Henriette Lindberg, Lisa Sengeløv
BACKGROUND: In the present study, we examined possible predictors of chemotherapy-induced toxicity, treatment outcomes, and the consequences of dose reductions in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving standard docetaxel. PATIENTS AND METHODS: Medical records from 421 consecutive patients treated with first-line docetaxel (75 mg/m(2) every 3 weeks) and low-dose prednisolone from 2007 to 2013 at Herlev University Hospital were reviewed...
March 24, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27057826/docetaxel-rechallenge-in-a-heavily-pretreated-patient-with-castration-resistant-prostate-cancer-a-case-report-and-review-of-literature
#19
REVIEW
Giuseppe Di Lorenzo, Martina Pagliuca, Teresa Perillo, Alfonso Benincasa, Davide Bosso, Sabino De Placido, Carlo Buonerba
Chemotherapy agents for patients with metastatic castration-resistant prostate cancer (mCRPC) include docetaxel and cabazitaxel. Although docetaxel is approved in the first-line treatment setting, a few studies have shown that selected patients can benefit from docetaxel rechallenge.We, here, report the case of a heavily pretreated mCRPC patient who reported clinical benefit from receiving docetaxel after previous exposure to docetaxel, cabazitaxel, abiraterone, and enzalutamide.After 4 cycles of treatment, patient's performance status had improved to 1, the hemoglobin level was 12...
April 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27004570/chemotherapy-following-radium-223-dichloride-treatment-in-alsympca
#20
RANDOMIZED CONTROLLED TRIAL
Oliver Sartor, Peter Hoskin, Robert E Coleman, Sten Nilsson, Nicholas J Vogelzang, Oana Petrenciuc, Karin Staudacher, Marcus Thuresson, Christopher Parker
BACKGROUND: Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium-223 treatment is of clinical importance. An exploratory analysis of prospectively collected data, from the ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) patient subgroup who received chemotherapy after radium-223 or placebo treatment, was conducted to evaluate the safety and efficacy of chemotherapy following radium-223...
July 2016: Prostate
keyword
keyword
79952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"